Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2019 16:05 ET | Source: Guardant Health, Inc.

Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming...
December 19, 2019 13:45 ET | Source: Guardant Health, Inc.

Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers

REDWOOD CITY, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announced that Palmetto GBA, a Medicare Administrative Contractor for the Molecular Diagnostics (MolDX)...
December 13, 2019 08:15 ET | Source: Guardant Health, Inc.

Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients

REDWOOD CITY, Calif., Dec. 13, 2019 (GLOBE NEWSWIRE) -- In the largest-ever liquid biopsy study for treatment selection in advanced breast cancer, investigators demonstrated in an 800-patient...
December 11, 2019 08:15 ET | Source: Guardant Health, Inc.

Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing

REDWOOD CITY, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Despite longstanding medical guidelines recommending biomarker testing for all patients with metastatic colon cancer, a new study published in...
November 07, 2019 16:03 ET | Source: Guardant Health, Inc.

Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance

REDWOOD CITY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
November 04, 2019 16:05 ET | Source: Guardant Health, Inc.

Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019

REDWOOD CITY, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2019 after market close on Thursday,...
October 23, 2019 16:03 ET | Source: Guardant Health, Inc.

Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening

REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its...
September 28, 2019 13:05 ET | Source: Guardant Health, Inc.

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health and the National Cancer Center Hospital East will present data at the European Society of Medical Oncology (ESMO) conference from...
August 06, 2019 16:05 ET | Source: Guardant Health, Inc.

Guardant Health Reports Second Quarter 2019 Financial Results and Raises 2019 Revenue Guidance

REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
August 05, 2019 08:00 ET | Source: Guardant Health, Inc.

Largest Study of its Kind Finds Guardant360 MSI Highly Concordant to Tissue

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- In the largest comparison of blood-based microsatellite instability (MSI) testing to traditional tissue methods across multiple solid tumor...